Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Ther Nucleic Acids
Hlavní autoři: Vinhas, Raquel, Fernandes, Alexandra R., Baptista, Pedro V.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Gene & Cell Therapy 2017
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436101/
https://ncbi.nlm.nih.gov/pubmed/28624216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2017.05.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky